Physician
Hematology
Dr. Angela M. Davies, MD
|
|
Give Review
Angela M. Davies works in the field of Hematology. She received awards:"Whos Who in Medicine and Healthcare". Angela M. Davies, MD has written publications. She has 55 publications published with PubMed. The lastest paper is: 'Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent ...'
Publications
- Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent ...
- Southwestern Oncology Group Phase II Trial (S0526) of Pemetrexed in Bronchioloalveolar Carcinoma Subtypes of Advanced Adenocarcinoma.
- Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial.
- Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003).
- Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
- Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study.
- EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
- Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
- Early clinical trial experience with vaccine therapies in non-small-cell lung cancer.
- Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
- The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
- Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
- Bevacizumab: optimal dose, schedule, and duration of therapy.
- Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
- Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
- Commentary: Oncologic drugs in patients with organ dysfunction: a summary.
- Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
- Incorporating bortezomib into the treatment of lung cancer.
- Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
- Optimizing targeted therapy in patients with lung cancer with a performance status of 2.
- Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.
- Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
- Aurora kinase inhibitors: a new class of targeted drugs in cancer.
- Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line.
- Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options.
- Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
- Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
- Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
- Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
- Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
- Treatment of extensive small cell lung cancer.
- Treatment of recurrent small cell lung cancer.
- Predictive molecular markers: has the time come for routine use in lung cancer?
- Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
- Antisense oligonucleotides in the treatment of non-small-cell lung cancer.
- Deletion of the distal long arm of chromosome 10; is there a characteristic phenotype? A report of 15 de novo and familial cases.
- The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-...
- An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.
- Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Gr...
- A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a ...
- Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
- Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
- Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
- Population-based phase I trial of irinotecan and epirubicin.
- The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
- Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer.
- Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
- Docetaxel in non-small cell lung cancer: a review.
- Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma.
- Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer.
- Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
- Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer.
- Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.
- Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Whos Who in Medicine and Healthcare
Helpful Reviews
Similar Doctors
|
|
Dr. Benjamin Y. Scheier, MD |
|
|
Dr. Eamon M. Berge, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Christopher H. Lieu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathryn L. Hassell, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Elaine T. Lam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine E. Klein, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Antonio Jimeno, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manali K. Kamdar, MD |
|
|
Dr. Andrew T. Johnson, MD |